An open label randomised controlled study to compare the efficacy, safety and tolerability of once each four weeks administration of subcutaneous C.E.R.A. versus darbepoetin alfa for the maintenance of haemoglobin levels in renal transplant recipients with chronic renal anaemia
Latest Information Update: 14 Apr 2022
At a glance
- Drugs Methoxy polyethylene glycol-epoetin beta (Primary) ; Darbepoetin alfa
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors Roche Farma
Most Recent Events
- 14 Apr 2022 New trial record